DK2465522T3 - Chemerin-15h og dets anvendelse til behandling af inflammation og endotoksisk shock - Google Patents

Chemerin-15h og dets anvendelse til behandling af inflammation og endotoksisk shock Download PDF

Info

Publication number
DK2465522T3
DK2465522T3 DK12152769.1T DK12152769T DK2465522T3 DK 2465522 T3 DK2465522 T3 DK 2465522T3 DK 12152769 T DK12152769 T DK 12152769T DK 2465522 T3 DK2465522 T3 DK 2465522T3
Authority
DK
Denmark
Prior art keywords
peptides
seq
treatment
chemerin
peptide
Prior art date
Application number
DK12152769.1T
Other languages
English (en)
Inventor
David R Greaves
Andreas Russ
Jenna L Cash
Original Assignee
Isis Innovation
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Isis Innovation filed Critical Isis Innovation
Application granted granted Critical
Publication of DK2465522T3 publication Critical patent/DK2465522T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/10—Peptides having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/08—Peptides having 5 to 11 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/02—Nasal agents, e.g. decongestants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/16—Otologicals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/04—Antihaemorrhagics; Procoagulants; Haemostatic agents; Antifibrinolytic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/06—Antianaemics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/06—Linear peptides containing only normal peptide links having 5 to 11 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Diabetes (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Dermatology (AREA)
  • Hematology (AREA)
  • Virology (AREA)
  • Zoology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Neurology (AREA)
  • Endocrinology (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
  • AIDS & HIV (AREA)

Claims (15)

1. Isoleret peptid bestående af (i) SEQ ID NO: 19; eller (ii) sekvensen i SEQ ID NO: 19 med én eller flere konservative aminosyresubstitutioner, hvor peptidet har mindst 80% sekvensidentitet med SEQ ID NO: 19.
2. Isoleret peptid ifølge krav 1, hvor peptidet eventuelt er acetyleret, acyleret, alkyleret eller glycosyleret.
3. Isoleret peptid ifølge krav 1 (del (ii)) eller krav 2, som har mindst 90% sekvensidentitet med SEQ ID NO: 19.
4. Isoleret peptid ifølge et hvilket som helst af de foregående krav, hvor peptidet er lige-kædet eller cyklisk; og/eller hvor peptidet omfatter en proteaseresistent grundstruktur.
5. Anvendelse af et isoleret peptid, som har mindst 80% sekvensidentitet med SEQ ID NO: 19, hvor peptidet eventuelt er acetyleret, acyleret, alkyleret eller glycosyleret, til fremstilling af et lægemiddel til behandling og/eller forebyggelse af endotoksisk shock; og/eller til reduktion af niveauet af én eller flere inflammatoriske mediatorer, såsom cytokiner og chemokiner; og/eller behandling af et sår; og/eller behandling og/eller forebyggelse af inflammation.
6. Anvendelse af ét eller flere peptider, der omfatter op til 30 aminosyrer, hvor det ene eller de flere peptider har en portion, der omfatter mindst 80% sekvensidentitet med SEQ ID NO: 19, eller hvor det ene eller de flere peptider har en portion, som har sekvensen i SEQ ID NO: 19, og hvor portionen kan omfatte én eller flere konservative aminosyresubstitutioner, og hvor det ene eller de flere peptider kan være acetyleret, acyleret, alkyleret og glycosyleret, til fremstilling af et lægemiddel til behandling af endotoksisk shock; og/eller til reduktion af niveauet af én eller flere inflammatoriske mediatorer; og/eller til behandling af et sår og/eller til behandling af inflammation.
7. Anvendelse ifølge krav 5 eller 6, hvor den ene eller de flere inflammatoriske mediatorer er valgt fra gruppen bestående af: TNFa, IL-1 a, IL-1 β, IL-6, G-CSF, MCP-2 (CCL-8), GROa (CXCL1), GR03 (CXCL2), IL-8 (CXCL8), TECK (CCL25), MCP-1 (CCL2), interferon γ og RANTES (CCL5).
8. Anvendelse ifølge et hvilket som helst af kravene 5 til 7, hvor peptidet er beregnet til administration i en dosis på mellem ca. 10 pg/kg og ca. 1 mg/kg.
9. Isoleret peptid ifølge et hvilket som helst af kravene 1-4 til anvendelse til behandling og/eller forebyggelse af endotoksisk shock; og/eller til anvendelse til reduktion af niveauet af én eller flere inflammatoriske mediatorer, såsom cytokiner og chemokiner; og/eller behandling af et sår; og/eller til anvendelse til behandling og/eller forebyggelse af inflammation.
10. Ét eller flere peptider, der omfatter op til 30 aminosyrer, hvor det ene eller de flere peptider har en portion, der omfatter mindst 80% sekvensidentitet med SEQ ID NO: 19, eller hvor det ene eller de flere peptider har en portion, som omfatter sekvensen i SEQ ID NO: 19, og hvor portionen kan omfatte én eller flere konservative aminosyresubstitu-tioner, og hvor det ene eller de flere peptider kan være acetyleret, acyleret, alkyleret og glycosyleret, til anvendelse til behandling og/eller forebyggelse af endotoksisk shock; og/eller til anvendelse til reduktion af niveauet af én eller flere inflammatoriske mediatorer, såsom cytokiner og chemokiner; og/eller til anvendelse til behandling af et sår og/eller til anvendelse til behandling og/eller forebyggelse af inflammation.
11. Sårforbinding, medicinsk indretning eller bandage, som er imprægneret med et isoleret peptid ifølge et hvilket som helst af kravene 1-4.
12. Sårforbinding, medicinsk indretning eller bandage, som er imprægneret med ét eller flere peptider, der omfatter op til 30 aminosyrer, hvor det ene eller de flere peptider har en portion, der omfatter mindst 80% sekvensidentitet med SEQ ID NO: 19, eller hvor det ene eller de flere peptider har en portion, som omfatter en sekvens i SEQ ID NO: 19, og hvor portionen kan omfatte én eller flere konservative aminosyresubstitutio-ner, og hvor det ene eller de flere peptider kan være acetyleret, acyleret, alkyleret og glycosyleret.
13. Farmaceutisk præparat, som omfatter et isoleret peptid ifølge et hvilket som helst af kravene 1-4 og en farmaceutisk acceptabel diluent, bærer eller excipiens.
14. Farmaceutisk præparat ifølge krav 13 til anvendelse til behandling og/eller forebyggelse af endotoksisk shock; og/eller til anvendelse til reduktion af niveauet af én eller flere inflammatoriske mediatorer, såsom cytokiner og chemokiner; og/eller til anvendelse til behandling af et sår; og/eller til anvendelse til behandling og/eller forebyggelse af inflammation.
15. Farmaceutisk præparat, der omfatter ét eller flere peptider, som omfatter op til 30 aminosyrer, hvor det ene eller de flere peptider har en portion, der omfatter mindst 80% sekvensidentitet med en sekvens i SEQ ID NO: 19, eller hvor det ene eller de flere peptider har en portion, som omfatter en sekvens i SEQ ID NO: 19, og hvor portionen kan omfatte én eller flere konservative aminosyresubstitutioner, og hvor det ene eller de flere peptider kan være acetyleret, acyleret, alkyleret og glycosyleret, og en farmaceutisk acceptabel diluent, bærer eller excipiens, hvor præparatet er til anvendelse til behandling og/eller forebyggelse af endotoksisk shock; og/eller til anvendelse til reduktion af niveauet af én eller flere inflammatoriske mediatorer; og/eller til anvendelse til behandling af et sår; og/eller til anvendelse til behandling af inflammation.
DK12152769.1T 2007-03-22 2008-03-25 Chemerin-15h og dets anvendelse til behandling af inflammation og endotoksisk shock DK2465522T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB0705488.5A GB0705488D0 (en) 2007-03-22 2007-03-22 Treatment of inflammation and/or endotoxic shock
EP08718857.9A EP2131852B1 (en) 2007-03-22 2008-03-25 Treatment of inflammation and/or endotoxic shock

Publications (1)

Publication Number Publication Date
DK2465522T3 true DK2465522T3 (da) 2014-11-17

Family

ID=38024621

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12152769.1T DK2465522T3 (da) 2007-03-22 2008-03-25 Chemerin-15h og dets anvendelse til behandling af inflammation og endotoksisk shock

Country Status (11)

Country Link
US (2) US8906865B2 (da)
EP (2) EP2465522B8 (da)
JP (2) JP2010522228A (da)
CN (2) CN102838658B (da)
AU (1) AU2008228012B2 (da)
CA (1) CA2684382A1 (da)
DK (1) DK2465522T3 (da)
ES (2) ES2523511T3 (da)
GB (1) GB0705488D0 (da)
PL (1) PL2465522T3 (da)
WO (1) WO2008114037A1 (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2010077339A2 (en) 2008-12-29 2010-07-08 Trevena, Inc. β-ARRESTIN EFFECTORS AND COMPOSITIONS AND METHODS OF USE THEREOF
JP2012233693A (ja) * 2009-08-26 2012-11-29 Sapporo Medical Univ 宿主対移植片疾患の検査方法
CN102772782B (zh) * 2011-05-06 2015-04-22 中国科学院上海生命科学研究院 一种新的肝癌分子标志物视黄酸受体应答蛋白2
JP2014530242A (ja) * 2011-10-13 2014-11-17 ガデック，トーマス 皮膚疾病の処置用のケメリンｃ１５ペプチドの局所製剤
JP6225121B2 (ja) 2012-01-31 2017-11-01 トレベナ・インコーポレイテッドＴｒｅｖｅｎａ， Ｉｎｃ． β−アレスチンエフェクターおよび組成物ならびにそれらの使用方法
CN102816209A (zh) * 2012-07-09 2012-12-12 深圳先进技术研究院 一种趋化素衍生肽及其表达基因和应用
PL236566B1 (pl) * 2012-12-17 2021-01-25 Univ Jagiellonski Peptyd chemerynowy, kompozycja farmaceutyczna zawierająca taki peptyd, oraz jego zastosowanie
EP3102223A4 (en) 2014-02-07 2017-11-29 Trevena, Inc. Crystalline and amorphous forms of a beta-arrestin effector
WO2015153838A1 (en) * 2014-04-02 2015-10-08 Rogne Bioscience Inc. Methods and compositions for treating inflammatory disorders
CN106456698B (zh) 2014-05-19 2022-05-17 特维娜有限公司 β-抑制蛋白效应物的合成
CN107449920B (zh) * 2017-08-10 2020-06-05 深圳先进技术研究院 一种趋化素及其衍生多肽的检测测试条及其制备方法
CN107583101A (zh) * 2017-09-27 2018-01-16 广州润虹医药科技股份有限公司 一种促进伤口愈合的生物膜制剂及其制备方法
DE102017127081B4 (de) 2017-11-17 2019-05-29 Sma Solar Technology Ag Verfahren zum Schwarzstart einer Energieversorgungseinrichtung, bidirektionaler Wechselrichter und Energieversorgungseinrichtung mit einem bidirektionalen Wechselrichter

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20030096299A1 (en) * 2001-07-09 2003-05-22 Valerie Wittamer Natural ligand of G protein coupled receptor ChemR23 and uses thereof
US7419658B2 (en) * 2001-07-09 2008-09-02 Euroscreen S.A. Isolated ligand of ChemerinR
US20050202029A1 (en) * 2003-10-03 2005-09-15 The Board Of Trustees Of The Leland Stanford Junior University Family of cystatin-related chemoattractant proteins

Also Published As

Publication number Publication date
PL2465522T3 (pl) 2015-02-27
WO2008114037A1 (en) 2008-09-25
CN102838658B (zh) 2016-10-05
JP5934298B2 (ja) 2016-06-15
CN101641114A (zh) 2010-02-03
GB0705488D0 (en) 2007-05-02
EP2131852B1 (en) 2017-11-01
US8906865B2 (en) 2014-12-09
ES2663379T3 (es) 2018-04-12
JP2010522228A (ja) 2010-07-01
JP2014237663A (ja) 2014-12-18
CN102838658A (zh) 2012-12-26
EP2131852A1 (en) 2009-12-16
WO2008114037A8 (en) 2009-07-16
ES2523511T3 (es) 2014-11-26
EP2465522B8 (en) 2014-11-19
CA2684382A1 (en) 2008-09-25
EP2465522B1 (en) 2014-08-13
AU2008228012A1 (en) 2008-09-25
AU2008228012B2 (en) 2014-01-30
EP2465522A1 (en) 2012-06-20
US20150320826A1 (en) 2015-11-12
CN101641114B (zh) 2014-03-12
US20100150990A1 (en) 2010-06-17

Similar Documents

Publication Publication Date Title
DK2465522T3 (da) Chemerin-15h og dets anvendelse til behandling af inflammation og endotoksisk shock
Colditz et al. In vivo inflammatory activity of neutrophil-activating factor, a novel chemotactic peptide derived from human monocytes.
EP1071449B1 (en) Use of an antagonist antibody to the inflammatory mediator oncostatin m (osm)
JP2003517846A (ja) 可溶性インターロイキン−２０レセプター
US20110177065A1 (en) Methods of treating/preventing inflammation using combination of il-1 antagonist and il-18 binding protein
CA2171761A1 (en) Eotaxin: eosinophil chemotactic cytokine
Sunyer et al. Evolution of anaphylatoxins, their diversity and novel roles in innate immunity: insights from the study of fish complement
WO1991008231A1 (en) [Ala IL-8]77 AS A LEUKOCYTE ADHESION INHIBITOR
US8221988B2 (en) Methods and compositions relating to CCR5 antagonist, IFN-γ and IL-13 induced inflammation
JP2023510864A (ja) グルカゴン、ｇｌｐ－１及びｇｉｐ受容体の全てに対して活性を有する三重活性体の持続型結合体の肺疾患の治療的使用
WO1998006751A9 (en) Mcp-3, rantes and mip-1alpha receptor antagonists
Perretti et al. Cytokines, glucocorticoids and lipocortins in the control of neutrophil migration
JP2004510426A (ja) 多発性硬化症の治療におけるケモカイン変異体
JP2020504161A (ja) 結核菌シャペロニン６０．１ペプチドおよびその使用
US5519000A (en) Tumor necrosis factor inhibitors
US5486595A (en) Tumor necrosis factor inhibitors
JP2005529099A (ja) 改善された経口生物学的利用能を有するケモカイン変異体
JP2001526061A (ja) β−リポトロピンおよびその使用
WO1995026744A1 (en) Tumor necrosis factor inhibitors